Comparison · NCT01991197-9f9bc4cf
Sitagliptin vs Gliclazide: The Number of Patricipants in the Sitagliptin and Gliclazide Arms With Adverse Events at 32 Weeks.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Sitagliptin vs Gliclazide: The Number of Patricipants in the Sitagliptin and Gliclazide Arms With Adverse Events at 32 Weeks. Trial comparisons, record NCT01991197-9f9bc4cf. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01991197-9f9bc4cf
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.667 | 0.354 | 0.879 | wilson | |
| Risk in group 2 | 0.909 | 0.623 | 0.984 | wilson | |
| Risk difference, group 1 minus group 2 | -0.242 | -0.564 | 0.114 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.733 | 0.446 | 1.21 | log | |
| Odds ratio, group 1 over group 2 | 0.2 | 0.0168 | 2.39 | log | |
| Number needed to treat, for one fewer participant with the outcome on Sitagliptin than on Gliclazide | 4.13 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Sitagliptin | Double blind phase (week 0-16):~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks.~Placebo Comparator: Gliclazide matched placebo One gliclazide matched placebo capsule daily for 4 weeks. If no severe hypoglycaemic episodes one gliclazide matched placebo capsule twice daily for 4 weeks. If no severe hypoglycaemic episodes two gliclazide matched placebo capsules twice daily for 8 weeks.~Open-label phase (week 16-32):~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks. | 6 | 9 | OG000 |
| Group 2 | Gliclazide | Double-blind phase (week 0-16):~Gliclazide 80mg once daily for 4 weeks Then if no severe hypoglycaemic episodes increase to Gliclazide 80mg twice daily for 4 weeks.~Then if no severe hypoglycaemic episodes increase to Gliclazide 160mg twice daily for 8 weeks Placebo Comparator: Sitagliptin matched placebo Two tablets (or one tablet in participants with moderate kidney disease) once daily for 16 weeks.~Open-label phase (week 16-32):~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks. | 10 | 11 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- The Number of Patricipants in the Sitagliptin and Gliclazide Arms With Adverse Events at 32 Weeks.
- Description
- Dosage: Sitagliptin: 100mg daily, or 50mg daily for participants with moderate kidney disease Gliclazide: 80-320 mg daily.~Secondary outcomes: the number participants with adverse events.
- Time frame
- 32 weeks
- Population
Source ClinicalTrials.gov
Trial
- Title
- Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.
- NCT number
- NCT01991197
- Phases
- PHASE2
- Conditions
- Psoriasis, Type 2 Diabetes Mellitus
- Interventions
- Sitagliptin, Gliclazide, Sitagliptin matched placebo, Gliclazide matched placebo capsule
- Lead sponsor
- University College Dublin
- Results first posted
- 2020-05-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01991197?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01991197-9f9bc4cf